Brief: Compass Therapeutics Provides Corporate Update
06/01/2026 13:52
Jan 6 (Reuters) - Compass Therapeutics Inc. CMPX.O: COMPASS THERAPEUTICS PROVIDES CORPORATE UPDATE COMPASS THERAPEUTICS INC. - PHASE 1 STUDY OF CTX-10726 EXPECTED TO START IN Q1 2026, INITIAL DATA EXPECTED H2 2026 COMPASS THERAPEUTICS INC. - PFS AND OS ANALYSES FOR TOVECIMIG IN BTC ON TRACK FOR Q1 2026 COMPASS THERAPEUTICS: INITIATION OF PHASE 2 TRIAL OF CTX-471 IN PATIENTS WITH TUMORS EXPRESSING NCAM (CD56) EXPECTED H1 2026 Source text: ID:nGNX92z6dT Further company coverage: CMPX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback